Swedish-based Molnlycke Health Care Invests $7 Million To Expand Its Rynel Plant In Wiscasset, Maine
“Mölnlycke Health Care’s business is expanding, both in the wound care and surgical business. The acquisition of Rynel is in line with our growth strategy. We want to continue the growth and innovation of our Advanced Wound Care business for the benefit of our customers. The acquisition of Rynel represents an important strategic milestone,” said CEO Pierre Guyot, when the firm was acquired.
As part of Mölnlycke, Rynel continues to be a premier manufacturer of specialty absorbent polyurethane foam products. As part of the purchase we have retained all of our employees including our management team, the parent company said.
“This is the kind of news that we like to see in the State of Maine: a large expansion of a good company that will add quality jobs for Maine residents,” said Gov. Paul R. LePage. “Stories like this only strengthen my resolve to make Maine a better place to do business and improve the lives of all Mainers through a thriving private sector. It’s a great example of what can happen when business and government work together.”
As an incentive the Town of Wiscasset’s Board of Selectmen has agreed to pursue a 20 year Tax Increment Financing deal on the company’s behalf.
This is Molnlycke’s second recent expansion in Maine. The company began constructing a new facility at Brunswick Landing earlier this year to manufacture wound care products, in which it intends to employ 45 people.
2023's Leading Metro Locations: Hotspots of Economic Growth
The Logistics Analysis That Drives Industrial Site Selection
2023 Top States for Doing Business Meet the Needs of Site Selectors
Technology’s Influence on Workforce Development
Workforce Q4 2023
AI 101 for Site Selection
First Person: Realizing the Inflation Reduction Act’s Full Potential
2023 Top States Commentary: Top-Ranked States Have What It Takes to Win Mega Projects